Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 18;22(1):56.
doi: 10.1186/s12978-025-02004-2.

Safety, immunogenicity, and effectiveness of chikungunya vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis

Affiliations

Safety, immunogenicity, and effectiveness of chikungunya vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis

Mabel Berrueta et al. Reprod Health. .

Abstract

Background: Chikungunya virus significantly impacts public health, primarily affecting regions in Africa and the Americas (predominantly Latin America and the Caribbean). Despite the global spread of the virus and its clinical manifestations and complications in vulnerable populations such as children and pregnant persons, no widely available vaccine is currently available. With recent advancements in vaccine development, there is a need to systematically evaluate the emerging evidence on the safety, immunogenicity, and efficacy of chikungunya vaccine candidates. This protocol outlines a living systematic review designed to continuously assess the growing research on chikungunya vaccines, focusing on diverse populations, including children and pregnant persons. We aim to provide up-to-date evidence to inform public health decisions and vaccine recommendations as new data is available.

Methods: Our objective is to carry out a living systematic review and meta-analysis through biweekly searches in medical databases and clinical trial registries, aiming to identify relevant chikungunya vaccines studies on pregnant individuals, children, and adolescents. Pairs of reviewers will independently screen studies, extract data, and assess the risk of bias. Clinical trials, quasi-experimental studies, and observational studies, including case reports, will be considered for inclusion. Main outcomes will include the safety, efficacy, and effectiveness of chikungunya vaccines in pregnant individuals (including neonatal outcomes), as well as in children and adolescents. Reactogenicity and immunogenicity will be considered as secondary outcomes. Paired meta-analyses, incorporating predefined subgroup and sensitivity analyses, will be performed. Evidence certainty will be assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.

Discussion: This living systematic review and meta-analysis will continuously assess the safety, immunogenicity, and effectiveness of chikungunya vaccines in pregnant persons, children, and adolescents. Given the significant disease burden and potential complications in these populations, synthesizing emerging evidence is crucial for guiding immunization policies and clinical recommendations. By maintaining an updated analysis, this review will provide timely insights for public health agencies, researchers, and clinicians involved in vaccine implementation and maternal-child health.

Study registration: Two protocols were registered in the International Prospective Register of Systematic Reviews database, CRD42024514513 and CRD42024516754.

Keywords: Chikungunya; Children, Protocol, Systematic review; Meta-analyses; Pregnancy; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics and dissemination: Ethical approval is not required for this study, given that this is a protocol for a systematic review and meta-analysis using published data. The systematic review and living meta-analysis results will be widely disseminated via the online dashboards described above. One or more summary papers will be submitted to a leading peer-reviewed journal in this field, adhering to the PRISMA statement/extension for reporting LSR. (56). Consent for publication: Not applicable. This study does not involve individual patient data or identifiable personal information requiring consent for publication. Competing interests: The authors declare no competing interests. Clinical trial number: Not applicable.

Similar articles

Cited by

References

    1. Burt FJ, Chen W, Miner JJ, Lenschow DJ, Merits A, Schnettler E, et al. Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis. 2017;17(4):e107–17. - PubMed
    1. Expansión geográfica de los casos de dengue y chikungunya más allá de las áreas históricas de transmisión en la Región de las Américas [Internet]. [cited 2025 Feb 5]. Available from: https://www.who.int/es/emergencies/disease-outbreak-news/item/2023-DON448
    1. de Souza WM, Ribeiro GS, de Lima STS, de Jesus R, Moreira FRR, Whittaker C, et al. Chikungunya: a decade of burden in the Americas. Lancet Reg Health Am. 2024;30(100673): 100673. - PMC - PubMed
    1. Skalinski LM, Santos AES, Paixão E, Itaparica M, Barreto F, da Conceição Nascimento Costa M, et al. Chikungunya seroprevalence in population-based studies: a systematic review and meta-analysis. Arch Public Health. 2023;81(1):80. - PMC - PubMed
    1. Bettis AA, L’Azou Jackson M, Yoon IK, Breugelmans JG, Goios A, Gubler DJ, et al. The global epidemiology of chikungunya from 1999 to 2020: a systematic literature review to inform the development and introduction of vaccines. PLoS Negl Trop Dis. 2022;16(1): e0010069. - PMC - PubMed

LinkOut - more resources